Key result
Lower lymphocyte-to-monocyte ratio and higher monocyte-to-HDL-C ratio independently predicted slow flow/no-reflow in NSTEMI patients undergoing PCI.
Why the study?
It was unclear whether inflammation-based scores, including NLR, PLR, LMR, and MHR, predict the slow flow/no-reflow phenomenon comparatively in patients with NSTEMI undergoing PCI.
Do inflammation-based scores (LMR and MHR) predict the slow flow/no-reflow phenomenon in NSTEMI patients undergoing PCI?
Observational (n=426)
Do inflammation-based scores (LMR and MHR) predict the slow flow/no-reflow phenomenon in NSTEMI patients undergoing PCI?
Answers are grounded in this paper and cite their sources.
LMR and MHR are useful inflammatory biomarkers for predicting the development of slow flow/no-reflow in NSTEMI patients undergoing PCI.
OBJECTIVE: To investigate whether inflammation based scores including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte to monocyte ratio (LMR) and monocyte to high-density lipoprotein cholesterol (HDL-C) ratio (MHR) predict the slow flow (SF)/no-reflow (NR) phenomenon comparatively in patients with non-ST-elevated Myocardial Infarction (NSTEMI) undergoing percutaneous coronary intervention (PCI). METHODS: Current study is retrospective designed and includes 426 NSTEMI patients (mean age of 56.8 ± 11.4 years). The patients were grouped into non slow flow/no-reflow and slow flow/no-reflow groups according to postintervention thrombolysis in myocardial infarction flow grade. RESULTS: The slow flow/no-reflow group had significantly higher MHR and lower LMR values than the non slow flow/no-reflow group (P < 0.01 and P < 0.01, respectively). Lower LMR [odds ratio (OR): 0.659, P < 0.01] and higher MHR (OR: 1.174, P = 0.04) were independent predictors of slow flow/no-reflow phenomenon in model 1 and 2 multivariate analyses, respectively. Furthermore, left ventricular ejection fraction (LVEF) (OR: 0.934, P = 0.01; OR: 0.930, P < 0.01), smoking (OR: 2.279, P = 0.03; OR: 2.118, P = 0.04), Syntax score (1.038, P = 0.04; 1.046, P = 0.01) and high thrombus grade (OR: 7.839, P < 0.01; OR: 8.269, P < 0.01), independently predicted the slow flow/no-reflow development in both multivariate analysis models, respectively. The predictive performance of LMR and MHR was not different (P = 0.88), but both predictive powers were superior to NLR (P < 0.01 and P = 0.03, respectively). CONCLUSION: The MHR and LMR may be useful inflammatory biomarkers for identifying high-risk individuals for the development of slow flow/no reflow in NSTEMI patients who underwent PCI.
No takes yet. Share an insight, caveat, or question.
Kalyoncuoğlu et al. (2020) conducted an observational in Non-ST-elevated Myocardial Infarction (NSTEMI) (n=426). Lymphocyte-to-monocyte ratio (LMR) and monocyte-to-HDL-C ratio (MHR) vs. Non slow flow/no-reflow group was evaluated on Slow flow/no-reflow phenomenon (OR 0.659, p=<0.01). Lower lymphocyte-to-monocyte ratio and higher monocyte-to-HDL-C ratio independently predicted slow flow/no-reflow in NSTEMI patients undergoing PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: